当前位置: 首页 >> 检索结果
81. Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation in Chinese Patients With Uncontrolled Hypertension: The Randomized, Sham-Controlled, Multi-Center Iberis-HTN Trial.
作者: Xiongjing Jiang.;Felix Mahfoud.;Wei Li.;Hui Dong.;Jing Yu.;Shuhua Yu.;Xiaoping Chen.;Peijian Wang.;Zhiqiang Li.;Lucas Lauder.;Zhifang Wang.;Zheng Ji.;Yifei Dong.;Bing Han.;Zhiming Zhu.;Yulin Chen.;Jianzhong Xu.;Xingsheng Zhao.;Weidong Fan.;Wen Xie.;Brad Hubbard.;Xi Hu.;Kazuomi Kario.;Runlin Gao.
来源: Circulation. 2024年150卷20期1588-1598页
Renal denervation (RDN) can lower blood pressure (BP) in patients with hypertension in both the presence and absence of medication. This is a sham-controlled trial investigating the safety and efficacy of RDN in China.
82. Flecainide to Prevent Atrial Arrhythmia After Patent Foramen Ovale Closure: AFLOAT Study, A Randomized Clinical Trial.
作者: Marie Hauguel-Moreau.;Paul Guedeney.;Claire Dauphin.;Vincent Auffret.;Jean-Michel Clerc.;Eloi Marijon.;Meyer Elbaz.;Philippe Aldebert.;Farzin Beygui.;Wissam Abi Khalil.;Antoine Da Costa.;Jean-Christophe Macia.;Simon Elhadad.;Guillaume Cayla.;Xavier Iriart.;Mikael Laredo.;Thomas Rolland.;Yassine Temmar.;Maria Elisabeta Gheorghiu.;Delphine Brugier.;Johanne Silvain.;Nadjib Hammoudi.;Guillaume Duthoit.;Abdourahmane Diallo.;Eric Vicaut.;Gilles Montalescot.; .
来源: Circulation. 2024年150卷21期1659-1668页
The real incidence of atrial arrhythmia (AA) after patent foramen ovale (PFO) closure and whether this complication can be prevented remain unknown. We assessed whether flecainide is effective to prevent AA during the first 3 months after PFO closure, and whether 6 months of treatment with flecainide is more effective than 3 months to prevent AA after PFO closure.
83. Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial.
作者: Milind Y Desai.;Yuichiro Okushi.;Andrew Gaballa.;Qiuqing Wang.;Jeffrey B Geske.;Anjali T Owens.;Sara Saberi.;Andrew Wang.;Paul C Cremer.;Mark Sherrid.;Neal K Lakdawala.;Albree Tower-Rader.;David Fermin.;Srihari S Naidu.;Kathy L Lampl.;Amy J Sehnert.;Steven E Nissen.;Zoran B Popovic.; .
来源: Circ Cardiovasc Imaging. 2024年17卷9期e017185页
In severely symptomatic patients with obstructive hypertrophic cardiomyopathy, VALOR-HCM (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy) demonstrated that mavacamten reduces the need for septal reduction therapy with sustained improvement in left ventricular (LV) outflow tract gradients and symptoms. Global longitudinal strain (GLS), a measure of regional myocardial function, is a more sensitive marker of systolic function. In VALOR-HCM, we assessed serial changes in LV and right ventricular (RV) strain.
84. Restrictive or Liberal Transfusion Strategy in Patients With Acute Myocardial Infarction and Anemia: 6-Month Mortality in the MINT Trial.
作者: Tabassome Simon.;Brandon M Herbert.;Maria Mori Brooks.;Shaun G Goodman.;John H Alexander.;Philippe Gabriel Steg.;Renato D Lopes.;Shahab Ghafghazi.;Claire Bouleti.;Howard A Cooper.;Eric L McCamant.;Kevin R Bainey.;Herbert D Aronow.;J Dawn Abbott.;Caroline Alsweiler.;Marnie Bertolet.;Dean A Fergusson.;Andrew M Goldsweig.;Paul C Hébert.;Jeffrey L Carson.; .
来源: Circulation. 2024年150卷13期1064-1066页 85. Randomized Invitation to Systematic NT-proBNP and ECG Screening in 75-Year-Olds to Detect Atrial Fibrillation: STROKESTOP II.
作者: Katrin Kemp Gudmundsdottir.;Emma Svennberg.;Leif Friberg.;Tove Hygrell.;Viveka Frykman.;Faris Al-Khalili.;Ziad Hijazi.;Mårten Rosenqvist.;Johan Engdahl.
来源: Circulation. 2024年150卷23期1837-1846页
Guidelines have suggested screening for atrial fibrillation to enable early treatment and avoid downstream negative clinical events. We aimed to determine whether atrial fibrillation screening potentially enhanced by NT-proBNP (N-terminal pro-B-type natriuretic peptide) would reduce stroke or systemic embolism incidence compared with a control group and to determine whether it was safe for those with low NT-proBNP concentrations to forfeit prolonged screening.
86. Zibotentan in Microvascular Angina: A Randomized, Placebo-Controlled, Crossover Trial.
作者: Andrew Morrow.;Robin Young.;George R Abraham.;Stephen Hoole.;John P Greenwood.;Jayanth Ranjit Arnold.;Mohamed El Shibly.;Mayooran Shanmuganathan.;Vanessa Ferreira.;Roby Rakhit.;Gavin Galasko.;Aish Sinha.;Divaka Perera.;Rasha Al-Lamee.;Ioakim Spyridopoulos.;Ashish Kotecha.;Gerald Clesham.;Thomas J Ford.;Anthony Davenport.;Sandosh Padmanabhan.;Lisa Jolly.;Peter Kellman.;Juan Carlos Kaski.;Robin A Weir.;Naveed Sattar.;Julie Kennedy.;Peter W Macfarlane.;Paul Welsh.;Alex McConnachie.;Colin Berry.; .
来源: Circulation. 2024年150卷21期1671-1683页
Microvascular angina is associated with dysregulation of the endothelin system and impairments in myocardial blood flow, exercise capacity, and health-related quality of life. The G allele of the noncoding single nucleotide polymorphism RS9349379 enhances expression of the endothelin-1 gene (EDN1) in human vascular cells, potentially increasing circulating concentrations of Endothelin-1 (ET-1). Whether zibotentan, an oral ET-A receptor selective antagonist, is efficacious and safe for the treatment of microvascular angina is unknown.
87. Relative Effectiveness of High-Dose Versus Standard-Dose Quadrivalent Influenza Vaccine in Older Adults With Cardiovascular Disease: A Prespecified Analysis of the DANFLU-1 Randomized Clinical Trial.
作者: Jacob Christensen.;Niklas Dyrby Johansen.;Daniel Modin.;Kira Hyldekær Janstrup.;Joshua Nealon.;Sandrine Samson.;Matthew Loiacono.;Rebecca Harris.;Carsten Schade Larsen.;Anne Marie Reimer Jensen.;Nino Emanuel Landler.;Brian L Claggett.;Scott D Solomon.;Gunnar H Gislason.;Lars Køber.;Martin J Landray.;Pradeesh Sivapalan.;Jens Ulrik Stæhr Jensen.;Tor Biering-Sørensen.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷2期e011496页
Influenza vaccination reduces the risk of adverse outcomes in patients with cardiovascular disease (CVD). We sought to evaluate whether the presence of CVD modified the relative effectiveness of the high-dose quadrivalent influenza vaccine (QIV-HD) versus standard-dose quadrivalent influenza vaccine (QIV-SD) in this prespecified analysis of the DANFLU-1 trial (Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine Versus Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting).
88. Enhancing Guidewire Efficacy for Transradial Access: The EAGER Randomized Controlled Trial.
作者: Adam C Bland.;William Meere.;Philopatir Mikhail.;Eunice Chuah.;Eleanor Redwood.;David Ferreira.;Nicklas Howden.;Adam Perkovic.;Samantha L Saunders.;Amy Kelty.;Tony Kull.;Andrew Hill.;Roberto Spina.;Kiran Sarathy.;Austin May.;Michael Parkinson.;Mark Ishak.;Nicholas Collins.;Andrew Boyle.;Maged William.;Prajith Jeyaprakash.;Tom J Ford.
来源: Circ Cardiovasc Interv. 2024年17卷10期e014529页
The 1.5 mm Baby J hydrophilic narrow J-tipped wire is a development of the standard 0.035" 3-mm J-tipped peripheral guidewire, designed to improve efficiency of transradial coronary procedures by safely navigating small caliber radial arteries to the aorta. There is currently a lack of evidence comparing the procedural success and safety of different peripheral guidewires used in transradial cardiac procedures. We compared the efficacy and safety of a narrow J-tipped hydrophilic 0.035" wire (intervention, Radifocus Baby J guidewire; TERUMO Co, Tokyo, Japan) versus a standard fixed-core 0.035" J wire (control).
89. Effect of Dapagliflozin on Accelerometer-Based Measures of Physical Activity in Patients With Heart Failure: An Analysis of the DETERMINE Trials.
作者: Kieran F Docherty.;Ruben Buendia Lopez.;Folke Folkvaljon.;Rudolf A de Boer.;Martin R Cowie.;Ann Hammarstedt.;Dalane W Kitzman.;Mikhail N Kosiborod.;Anna Maria Langkilde.;Barry Reicher.;Michele Senni.;Sanjiv J Shah.;Subodh Verma.;Scott D Solomon.;John J V McMurray.
来源: Circ Heart Fail. 2024年17卷10期e012349页
Wearable accelerometers can quantify the frequency and intensity of physical activity during everyday life and may provide complementary data to established functional outcome measures on the effect of heart failure therapies on functional limitations.
90. Impact of Physical Activity in Patients With Atrial Fibrillation Undergoing Catheter Ablation: The Multicenter Randomized BE-ACTION Trial.
作者: Martin Seifert.;Daniel Meretz.;Anja Haase-Fielitz.;Christian Georgi.;Marwin Bannehr.;Viviane Moeller.;Gerhard Janßen.;Peter Bramlage.;Hans Heinrich Minden.;Dirk Grosse-Meininghaus.;Christian Butter.
来源: Circ Cardiovasc Qual Outcomes. 2024年17卷10期e010877页
Arrhythmia recurrence after pulmonary vein isolation (PVI) is common. We conducted a multicenter, randomized trial to determine the impact of increased physical activity on atrial fibrillation recurrence after PVI.
91. Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF Trial.
作者: Henri Lu.;Safia Chatur.;Sahmin Lee.;Riccardo M Inciardi.;Martin Abanda.;Finnian R Mc Causland.;Arzu Kalayci.;Kimia Karimi Taheri.;Amil M Shah.;Maja Cikes.;Brian L Claggett.;Narayana Prasad.;Carolyn S P Lam.;Eileen O'Meara.;Xiaowen Wang.;John J V McMurray.;Marc A Pfeffer.;Sheila M Hegde.;Scott D Solomon.;Hicham Skali.
来源: Circ Heart Fail. 2024年17卷10期e011942页
Renal dysfunction is common and associated with a poor prognosis in patients with heart failure. However, the association of cardiac structure and function with decline in kidney function in this population is unknown. We aimed to assess the association between individual measures of cardiac structure and function with changes in renal function and renal outcomes in patients with heart failure with preserved ejection fraction.
92. Restrictive Versus Liberal Transfusion in Patients With Type 1 or Type 2 Myocardial Infarction: A Prespecified Analysis of the MINT Trial.
作者: Andrew P DeFilippis.;J Dawn Abbott.;Brandon M Herbert.;Marnie H Bertolet.;Bernard R Chaitman.;Harvey D White.;Andrew M Goldsweig.;Tamar S Polonsky.;Rajesh Gupta.;Caroline Alsweiler.;Johanne Silvain.;Pedro G M de Barros E Silva.;Graham S Hillis.;Benoit Daneault.;Meechai Tessalee.;Mark A Menegus.;Sunil V Rao.;Renato D Lopes.;Paul C Hébert.;John H Alexander.;Maria M Brooks.;Jeffrey L Carson.;Shaun G Goodman.; .
来源: Circulation. 2024年150卷23期1826-1836页
The MINT trial (Myocardial Ischemia and Transfusion) raised concern for harm from a restrictive versus liberal transfusion strategy in patients with acute myocardial infarction (MI) and anemia. Type 1 and type 2 MI are distinct pathophysiologic entities that may respond differently to blood transfusion. This analysis sought to determine whether the effects of transfusion varied among patients with a type 1 or a type 2 MI and anemia. The authors hypothesized that the liberal transfusion strategy would be of greater benefit in type 2 than in type 1 MI.
93. Proteomics Identify Clinical Phenotypes and Predict Functional Outcomes in Heart Failure With Preserved Ejection Fraction: Insights From VITALITY-HFpEF.
作者: Christopher R deFilippi.;Palak Shah.;Sanjiv J Shah.;Wendimagegn Alemayehu.;Carolyn S P Lam.;Javed Butler.;Lothar Roessig.;Christopher M O'Connor.;Cynthia M Westerhout.;Paul W Armstrong.; .
来源: Circ Heart Fail. 2024年17卷9期e011792页
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome that may emerge from overlapping systemic processes associated with comorbidities. We assessed whether unique clusters of circulating proteins are associated with specific clinical characteristics and functional status at baseline and follow-up in a well-phenotyped cohort of patients with HFpEF.
94. Analysis of the PARAGON-HF Study Results Using Win Ratio.
作者: Minjae Yoon.;Wonse Kim.;Woong Kook.;Jin Joo Park.;Barry Greenberg.
来源: Circ Heart Fail. 2024年17卷9期e011860页
The PARAGON-HF study (Prospective Comparison of ARNI With ARB Global Outcomes in Heart Failure With Preserved Ejection Fraction) investigated the effect of sacubitril-valsartan in heart failure (HF) with preserved ejection fraction. The results, which were analyzed using conventional statistical methods, did not find a significant reduction in the primary composite end point of cardiovascular death and total hospitalization for HF. Recent clinical trials used win ratio statistics that enable the incorporation of multiple outcome aspects into the primary end point and can detect positive outcomes with fewer patients. In this study, we assessed the effect of sacubitril-valsartan on outcomes using the win ratio to analyze results from patients included in the PARAGON-HF study.
95. Serum Chloride and the Response to Acetazolamide in Patients With Acute Heart Failure and Volume Overload: A Post Hoc Analysis From the ADVOR Trial.
作者: Jef Van den Eynde.;Pieter Martens.;Jeroen Dauw.;Petra Nijst.;Evelyne Meekers.;Jozine M Ter Maaten.;Kevin Damman.;Gerasimos Filippatos.;Johan Lassus.;Alexandre Mebazaa.;Frank Ruschitzka.;Matthias Dupont.;Wilfried Mullens.;Frederik H Verbrugge.
来源: Circ Heart Fail. 2024年17卷10期e011749页
Chloride plays a crucial role in renal salt sensing. This study investigates whether serum chloride is associated with clinical outcomes and decongestive response to acetazolamide in patients with acute decompensated heart failure.
96. Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial.
作者: Miao Yu.;Yong Yang.;Si-Lai Dong.;Chen Zhao.;Fen Yang.;Yuan-Fan Yuan.;Yu-Hua Liao.;Shao-Lin He.;Kun Liu.;Fen Wei.;Hai-Bo Jia.;Bo Yu.;Xiang Cheng.
来源: Circulation. 2024年150卷13期981-993页
Colchicine has been approved to reduce cardiovascular risk in patients with coronary heart disease on the basis of its potential benefits demonstrated in the COLCOT (Colchicine Cardiovascular Outcomes Trial) and LoDoCo2 (Low-Dose Colchicine 2) studies. Nevertheless, there are limited data available about the specific impact of colchicine on coronary plaques.
97. Effects of Sedentary Behavior Reduction on Blood Pressure in Desk Workers: Results From the RESET-BP Randomized Clinical Trial.
作者: Bethany Barone Gibbs.;Subashan Perera.;Kimberly A Huber.;Joshua L Paley.;Molly B Conroy.;John M Jakicic.;Matthew F Muldoon.
来源: Circulation. 2024年150卷18期1416-1427页
Sedentary behavior (SB) is observationally associated with cardiovascular disease risk. However, randomized clinical trials testing causation are limited. We hypothesized that reducing SB would decrease blood pressure (BP) and pulse wave velocity (PWV) in sedentary adults.
98. Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.
作者: Nigopan Gopalasingam.;Kristoffer Berg-Hansen.;Kristian Hylleberg Christensen.;Bertil T Ladefoged.;Steen Hvitfeldt Poulsen.;Mads Jønsson Andersen.;Barry A Borlaug.;Roni Nielsen.;Niels Møller.;Henrik Wiggers.
来源: Circulation. 2024年150卷20期1570-1583页
Heart failure with preserved ejection fraction (HFpEF) is a major cause of morbidity and mortality in patients with type 2 diabetes (T2D). Acute increases in circulating levels of ketone body 3-hydroxybutyrate have beneficial acute hemodynamic effects in patients without T2D with chronic heart failure with reduced ejection fraction. However, the cardiovascular effects of prolonged oral ketone ester (KE) treatment in patients with T2D and HFpEF remain unknown.
99. Long Term Outcomes After Renal Revascularization for Atherosclerotic Renovascular Disease in the ASTRAL Trial.
作者: Hannah O'Keeffe.;Darren Green.;Aine de Bhailis.;Rajkumar Chinnadurai.;Keith Wheatley.;Jonathan Moss.;Philip A Kalra.; .
来源: Circ Cardiovasc Interv. 2024年17卷9期e013979页
The ASTRAL trial (Angioplasty and Stenting for Renal Artery Lesions) recruited 806 patients between 2000 and 2007. Patients with atherosclerotic renal artery stenosis (RAS) and clinician uncertainty about the benefit of revascularization were randomized 1:1 to medical therapy with or without renal artery stenting. The initial results were presented in 2009 at a median 33.6-month follow-up, with no benefit of revascularization on renal or cardiovascular outcomes. Surviving patients remained under follow-up until the end of 2013, and the long-term results are presented in this study.
100. Results of International, Double-Blind, Randomized, Placebo-Controlled, Phase IIa Study of Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment-Elevation Myocardial Infarction (STEMI).
作者: Antonio Abbate.;Benjamin Van Tassell.;Vlad Bogin.;Roshanak Markley.;Dmitry V Pevzner.;Paul C Cremer.;Imad Meray.;Dmitry V Privalov.;Angela Taylor.;Sergey A Grishin.;Alina N Egorova.;Ekaterina G Ponomar.;Yan Lavrovsky.;Mikhail Yu Samsonov.; .
来源: Circulation. 2024年150卷7期580-582页 |